Literature DB >> 8806698

Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene.

R Sánchez-Prieto1, M Quintanilla, A Cano, M L Leonart, P Martin, A Anaya, S Ramón y Cajal.   

Abstract

Squamous cell carcinomas can show different oncogenic alterations, histological patterns, and an unpredictable clinical behavior. We previously reported that the adenovirus E1a gene may induce sensitivity to DNA-damaging agents in mouse keratinocytes. In order to study whether E1a expression could be used as a therapeutic agent in different malignant cell lines carrying mutations on the p53 gene and other oncogenic alterations, we transfected and infected several murine and human carcinoma cell lines (HaCa4; MSC11A5; HeLa) with vectors containing the 13S or 12S E1a region. We evaluated the sensitivity to cisplatin (CDDP), doxorubicin (DOX) and gamma irradiation (RX) by the crystal violet method. The induction of apoptosis was assessed by flow cytometry and presence of DNA ladders in agarose gels. The expression of E1a and the tumor suppressor p53 protein was analysed by Western blotting. The carcinoma cell lines expressing E1a were about four- to tenfold more sensitive to CDDP and RX, respectively, than the control cells. Moreover, the reduction in cell viability and cell growth after exposure to CDDP or RX was very significant in the carcinoma cells expressing E1a. With these results, we conclude that expression of E1a may confer great sensitivity to DNA-damaging agents on squamous cell carcinoma cells independently of the p53 protein status and other oncogenic alterations.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806698

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

1.  Immune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?

Authors:  Jay D Naik; Christopher J Twelves; Peter J Selby; Richard G Vile; John D Chester
Journal:  Clin Cancer Res       Date:  2011-05-16       Impact factor: 12.531

2.  5-Fluorouracil-related enhancement of adenoviral infection is Coxsackievirus-adenovirus receptor independent and associated with morphological changes in lipid membranes.

Authors:  Chiara Cabrele; Mandy Vogel; Pompiliu Piso; Markus Rentsch; Josef Schröder; Karl W Jauch; Hans J Schlitt; Alexander Beham
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742

3.  E1a promotes c-Myc-dependent replicative stress: implications in glioblastoma radiosensitization.

Authors:  María Llanos Valero; Francisco Jose Cimas; Laura Arias; Pedro Melgar-Rojas; Elena García; Juan Luis Callejas-Valera; Jesús García-Cano; Leticia Serrano-Oviedo; Miguel Ángel de la Cruz-Morcillo; Isabel Sánchez-Pérez; Ricardo Sánchez-Prieto
Journal:  Cell Cycle       Date:  2013-10-11       Impact factor: 4.534

4.  DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells.

Authors:  Andrea Cuconati; Chandreyee Mukherjee; Denise Perez; Eileen White
Journal:  Genes Dev       Date:  2003-11-21       Impact factor: 11.361

5.  Role of the E1A Rb-binding domain in repression of the NF-kappa B-dependent defense against tumor necrosis factor-alpha.

Authors:  James L Cook; Thomas A Walker; G Scott Worthen; Jay R Radke
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-15       Impact factor: 11.205

6.  Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions.

Authors:  Joshua C Doloff; David J Waxman; Youssef Jounaidi
Journal:  Hum Gene Ther       Date:  2008-12       Impact factor: 5.695

7.  Docetaxel increases antitumor efficacy of oncolytic prostate-restricted replicative adenovirus by enhancing cell killing and virus distribution.

Authors:  Xiong Li; Youhong Liu; Yong Tang; Phipps Roger; Meei-Huey Jeng; Chinghai Kao
Journal:  J Gene Med       Date:  2010-06       Impact factor: 4.152

8.  Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin.

Authors:  H C A Graat; M A Witlox; F H E Schagen; G J L Kaspers; M N Helder; J Bras; G R Schaap; W R Gerritsen; P I J M Wuisman; V W van Beusechem
Journal:  Br J Cancer       Date:  2006-05-30       Impact factor: 7.640

Review 9.  The feasibility of gene therapy in the treatment of head and neck cancer.

Authors:  Emanuela Vattemi; Pier Paolo Claudio
Journal:  Head Neck Oncol       Date:  2009-01-12

10.  Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts.

Authors:  B Geoerger; J Grill; P Opolon; J Morizet; G Aubert; Y Lecluse; V W van Beusechem; W R Gerritsen; D H Kirn; G Vassal
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.